The protostane-type triterpenes from Alisma orentalis were revealed to have anti-HBV activity. Further chemical modification on the active compound alisol A provided 41 more active compounds from 154 synthezed derivatives. A significantly active compound with lower toxicity and good pharmacokinetic characteristic can act on the HBV C/preC and the X gene promoters, inhibit DHBV DNA load, and do not result in rebound of DHBV DNA load after stop of administration. Seven novel class of iridoidal lactones with potential anti-HBV activity were revealed from Swertia mileensis, and their biogenetic pathway were proposed. Furthermore, four kinds of alkaloids and synthetic quinolin-2-ones and quinolines were revealed to possess potential anti-HBV activity.
A promising compound with significantly antidepressant activity and a new mechanism from a mediacinal herb has been elucidated as a new antidepressant drug. The pre-clinical studies of the new drug, including quality control standard, manufacturing process, pharmacologic and mechanism investigation in vivo, toxicology pharmacology and pharmacokinetics, have been accomplished, which resulted in the approval of phases I, II and III clinical trials by SFDA.
Novel skeleton of the indole alkaloids from leaves of Isatis tinctoria and three classes of components with anti-HIV-1 activity were discovered from ten species of TCMs.
Recently, more than 500 compounds from 20 specices of TCMs, including 7 new classes of the skeleton and more than 100 new compounds had been isolated, and about 60 peer reviewed articles, including 36 papers in SCI journals had been published, 22 items of domestic and international patents had been applied.
Location: 
